NEW YORK, January 26, 2017 /PRNewswire/ --
The small-cap market is often overlooked. Yet under certain conditions small caps can be a good place to look if certain
measures are taken. These are high-risk high-reward companies, therefore extensive due diligence is required. A small cap company
with potential will have a record of consistent public filings and strong management. Often, the current political environment
may also have an effect on small cap companies. For example, certain policies of a new presidential administration, like
increasing tariffs or starting a trade war, will be beneficial for small companies, explained Hank
Smith, chief investment officer at Haverford Trust. Such policies, "would favor small stocks, which are domestically
orientated, at the expense of the multinationals that make up the S&P 500." He told MarketWatch. Cell MedX Corp. (OTCQB:
CMXC), Pura Naturals Inc. (OTCQB: PNAT), Federal National Mortgage Association (OTCQB: FNMA), Paladin Energy Ltd (OTC: PALAF),
PharmaCyte Inc. (OTCQB: PMCB)
The new presidential administration also promised to significantly reduce business regulations, which also may be beneficial
for small companies, as they are less equipped to deal with regulations and the expenses that ensue. Bruce Bittles, chief investment strategist at Robert W. Baird & Co. said, "Small-caps have been punished
by overregulation because it is harder for them to absorb the impact of the regulation... Large companies are better equipped to
deal with increased client costs, legal expenses."
Cell MedX Corp. (OTCQB: CMXC) is an early development stage bio-tech company focused on the discovery, development and
commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications
associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, high blood pressure.
Earlier this week Cell MedX Corp. announced that it has received an approval from Health Canada to commence its observational
clinical trial in Canada. The company revealed that it will, "launch the observational clinical
trial of its innovative and proprietary technology branded under the trade name eBalance. The intent of the Trial is to assess
the impact of eBalance therapy as an adjunct treatment on HbA1c after three months of therapy in relation to the subject's
baseline data and medical history. Additional objectives of the Trial will be to assess the effect of eBalance therapy on insulin
resistance and sensitivity as well as on various complications caused by diabetes."
Chief Executive Officer and President of Cell MedX Corp. Frank McEnulty said in a statement, "I
am very excited to receive the approval from Health Canada in that it allows us to further advance research of our eBalance
technology as well as its effects on both diabetes and diabetic complications."
Pura Naturals Inc. (OTCQB: PNAT) launched a division focused on developing solutions using AirTech Foam technologies
and allied products directed towards oil spill prevention and remediation in our waterways, known as the Pura Marine. Pura Marine
is currently in negotiations with some of the largest marine oil transport companies in the United
States and in addition is actively pursuing business in the trucking and oil sectors. "We are dedicated to focusing our
proprietary technologies on industries and markets where we can provide better solutions for current challenges and unmet needs,"
said Derek Duhame, President of Pura Naturals, Inc.
Federal National Mortgage Association (OTCQB: FNMA) priced its first Multifamily DUS® REMIC in 2017 totaling
$1.04 billion under its Fannie Mae Guaranteed Multifamily Structures program on January 18, 2017. "Agency CMBS has become a recognized asset class, led by Fannie Mae DUS MBS. We issued more
than $55 billion in multifamily MBS last year, plus another $10
billion in GeMS new issuance - significantly more than any other securitized multifamily platform," said Josh Seiff, Fannie Mae's Vice President of Capital Markets and Trading. "FNA 2017-M1 continued the trend -
more than 40 investors were involved in the deal, which included 111 loans and was just over $1.0
billion in size. We're looking forward to another market-leading year for the Fannie Mae DUS platform in 2017."
Paladin Energy Ltd (OTC: PALAF) is a uranium production company with projects currently in Australia and two mines in Africa with a strategy to become a major uranium
mining house. Since 1998, during a period of sustained downturn in global uranium markets, Paladin accumulated a quality
portfolio of advanced uranium projects each having production potential. The Langer Heinrich Mine in Namibia is Paladin's flagship project. The Company has completed a Stage 3 expansion and is now producing at
a 5.2Mlb per annum rate. The Kayelekera Mine in Malawi, the Company's second mine, provided an
excellent follow-up to Langer Heinrich.
In an upcoming clinical trial by biotech company, PharmaCyte Inc. (OTCQB: PMCB), will consist of patients who have
inoperable pancreatic cancer that has not yet spread from the pancreas where it first started to any other place in the body.
Patients must also have tumors that no longer respond to the combination chemotherapy treatment of Abraxane® plus gemcitabine
after they've been on that treatment for a period of between 4 and 6 months. The company's new trial design calls for multiple
cycles of ifosfamide to be given to those patients being treated with PharmaCyte's pancreatic cancer therapy. This will continue
until the patients' tumors no longer respond to PharmaCyte's therapy or until treatment-related toxicity accumulates to
unacceptable levels.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts
on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and
advertising for third parties for disseminating news and original content through our unique media platform that includes
Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into
service agreements with the companies which are the subject to the articles posted on the Site or other editorials for
advertising such companies. Financialbuzz.com has not been compensated directly by any of the companies mentioned here in this
editorial. We are not an independent news media provider and therefore do not represent or warrant that the information posted on
the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and
sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer
any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com
only regurgitates financial or corporate news through our unique financial newswire and media platform. FinancialBuzz.com has
been compensated a total of twenty one thousand dollars for financial news dissemination and pr
services by a third party non affiliate for cell medx corp. Our fees may be either a flat cash sum or negotiated number of
securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of
which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement.
FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising.
FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any
companies the information contained herein is not intended to be used as the basis for investment decisions and should not be
considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy,
hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from
the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes
electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own
independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By
accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended
from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase,
hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor.
This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular
security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and
tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions.
We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to
change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not
guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact: info@financialbuzz.com , +1-877-601-1879
Url: FinancialBuzz.com
SOURCE FinancialBuzz.com